ARNA
Arena Pharma
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 4.36B; Volume: 90.14K; AvgVol 3m: 522.64K; Beta: –;
Cost estimate:
P/E: –; EPS: -6.83; EPS growth quarter/prev quarter: -30.10%;
EPS growth this year: -197.50%; EPS growth past 5 years: 36.80%;
EPS ttm: -6.83;
P/S: 976.45; P/B: 3.28; P/Cashflow: 3.84; P/FCF: ;
Sales: 4.61M; Sales growth quarter/prev quarter: ; Sales growth past 5 years: 85.20%;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -28.60%; ROE – return on equity: -31.10%; LT Debt/Equity: 0.04; Total Debt/Equity: 0.04;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.10%; Insider Transactions:-86.46%;
Institutional Ownership: 94.00%; Institutional Transactions: 19.06%;
Data update: 07/10/2020.